I'll research HIG (The Hartford Financial Services Group) before writing the preview. Let me gather recent earnings, filings, and news.Let me read the most recent earnings materials (Q1 2026 call and release) and the prior year Q2 for comparison.Let me get the year-ago Q2 2025 base (the comparison quarter), recent stock price, and consensus estimates.Let me check analyst consensus expectations and any recent sector news.Let me fix the web search to get consensus estimates.I have what I need. One quick calc on the stock reaction and setup, then I'll write.Here is the earnings preview.
Report date: After the close, Wednesday, July 22, 2026 · Call: Thursday, July 23, 2026, 2026Q2 Earnings Call Recent price: ~$140.87 (7/22) · BVPS: $66.58 · BVPS ex-AOCI: $75.25 (~1.9x) · TTM core ROE: 20.3%
The Hartford enters this print as a high-quality compounder firing on most cylinders (20%+ trailing core ROE), but against the toughest comparison of the year. A year ago, Q2 2025 was an "outstanding" quarter — core earnings of nearly $1 billion ($3.41/share), a sub-88 Business Insurance underlying combined ratio, a 9.2% Employee Benefits margin, and $163M of favorable prior-year development. Beating or matching that bar while the P&C pricing cycle is visibly softening is the central tension in this report.
| Metric | Q2 2025 (comp) | Q1 2026 (latest) |
|---|---|---|
| Core EPS | $3.41 | $3.09 |
| Core earnings | $981M | $866M |
| Consolidated NII (pre-tax) | $664M | $739M |
| Business Insurance WP growth | +8% | +6% |
| BI underlying combined ratio | 88.0 | 89.2 |
| Personal Insurance WP growth | +7% | ‑6% |
| PI underlying combined ratio | 88.0 | 85.0 |
| Employee Benefits core margin | 9.2% | 6.9% |
| Favorable PYD (core, pre-tax) | +$163M | +$5M |
| P&C CAY CAT losses (pre-tax) | $212M | $230M |
1. Business Insurance pricing discipline vs. a softening market. This is the most-debated issue. Management held ex-comp renewal pricing at ~6% in Q1 (down just 10 bps sequentially) while peers decelerated more, and leaned into strong liability pricing (GL ~9.7%, umbrella/excess in low double digits) and property (targeting ~10% property premium growth in 2026 off a $3.3B base). Watch whether Small Business can sustain ~8% growth, and whether Middle & Large / Global Specialty pricing holds as competition intensifies and business flows back to admitted markets. Any BI underlying combined ratio drift materially above ~89–90 will draw scrutiny.
2. Workers' comp margin. Management has flagged "modest" comp margin pressure in 2026 with pricing roughly flat and severity running ~3–3.5% (inside the 5% pick). Comp is a key swing factor within the BI loss ratio.
3. Catastrophes and the aggregate treaty. Q2 is peak season for tornado/wind/hail. Q2 2025 CATs were $212M. The aggregate reinsurance treaty attaches at $750M of subject losses (ex-Global Re), and HIG was only at ~$204M through Q1 — so a heavy convective-storm quarter is a real earnings risk with limited near-term reinsurance offset.
4. Personal Insurance — margin holding, growth shrinking. Auto premium is contracting (‑10% in Q1) as HIG refuses to chase competitors cutting rates. The bull case rests on the agency-channel "Prevail" rollout (live in 15 states in Q1, targeting 30 by early 2027) reaccelerating growth without sacrificing the hard-won ~85 underlying combined ratio. Watch retention trends as pricing moderates (auto renewal pricing was 6.8% in Q1, expected to keep decelerating).
5. Employee Benefits margin — tough comp. Q2 2025's 9.2% core margin is a high hurdle. The disability loss ratio has been creeping up on higher short-term disability/Paid Family & Medical Leave utilization (management is pushing double-digit PFML rate increases), and the expense ratio is rising on tech/staffing investment. Watch whether the margin stabilizes above ~7% and whether the strong sales momentum continues.
6. Reserves / social inflation. After the Q1 legacy A&M/GL top-up, investors will look for confirmation that core general-liability and casualty picks remain adequate and that favorable comp/home/auto development continues. Note that PYD is a large, lumpy swing item — Q2 2025's $163M favorable will be hard to repeat.
7. Investment income & alternatives. NII has been a tailwind (higher rates + growing invested assets). Management guided full-year 2026 NII to grow with yields roughly in line with 2025, but flagged that LP/alternative returns may stay soft given market volatility. Also expect continued questions on private credit / direct-lending / BDC exposure (~2% of invested assets, <1% BDC) given sector concerns.
8. Capital return. Management guided to another ~$450M of buybacks in Q2 (~$1.1B authorization remained through year-end 2026 as of March). Steady buyback + dividend cadence is part of the story.
9. Governance note. HIG added Randy Larsen to its board and key committees (announced 7/15/2026) — minor, but the only fresh company-specific news since Q1.
Expect the narrative to hinge less on the headline EPS and more on three swing factors: the Business Insurance underlying margin/pricing trajectory, catastrophe experience, and whether Employee Benefits margins stabilize. Given the exceptional Q2 2025 comp (very favorable CATs, huge PYD, 9.2% EB margin), the bar for a clean year-over-year "beat" is high. The most likely path to a positive reaction is continued pricing resilience in commercial lines, a benign cat quarter, sustained Personal Insurance margin, and reassurance on reserve adequacy and capital return — while the biggest risk is a heavy convective-storm quarter or further EB/disability and workers'-comp margin erosion landing on an already premium-valued stock.
(One housekeeping flag: the Q1 transcript labels the CFO "Beth Bombara," but the company's press releases name the CFO as Beth Costello — the transcript appears to be a mis-transcription.)
Preview based on HIG's Q1 2026 and Q2 2025 earnings releases and the Q1 2026 earnings call, recent price action through 7/22/2026, and the 7/15/2026 board-appointment disclosure. Forward-looking watch items reflect management's own commentary and guidance; actual results and any updated consensus estimates should be confirmed against the release.